Objective:Danhong injection(DHI)is commonly used in China to treat chronic stable angina(CSA),demonstrating significant clinical efficacy and safety.The present study aimed to estimate the cost-effectiveness of DHI co...Objective:Danhong injection(DHI)is commonly used in China to treat chronic stable angina(CSA),demonstrating significant clinical efficacy and safety.The present study aimed to estimate the cost-effectiveness of DHI combined with standard treatment(ST)compared with ST alone in patients with CSA.Methods:A Markov model with a 3-month cycle and a 1-year time horizon was used to assess the cost-effectiveness of DHI+ST for CSA.Health outcomes were measured as quality-adjusted life years(QALYs),and societal perspective costs were collected in China.Cost-effectiveness was evaluated using the incremental cost-effectiveness ratio(ICER).Sensitivity analysis was performed to test the robustness of results to parameter uncertainty.Results:Analysis demonstrated DHI+ST provided 0.8190 QALYs at an average cost of$3644.24,while ST yielded 0.7884 QALYs costing$2739.54 over 1 year.The incremental analysis indicated DHI+ST dominance,with an ICER of$29,588.91 per QALY gained compared with ST.One-way sensitivity analysis confirmed the robustness of base case findings,and probabilistic sensitivity analysis suggested a 61.66%probability of DHI+ST being cost-effective over ST at a$37,663.26 per QALY threshold.Conclusion:From a societal perspective in China,DHI+ST appears cost-effective for the treatment of CSA compared with ST alone.These findings support recommending DHI as a clinically valuable and cost-effective option in CSA treatment guidelines.展开更多
目的丹红注射液对急性冠脉综合征(ACS)患者血浆脑钠肽(BNP)及心率变异性(HRV)的影响。方法选取我院收治的急性冠脉综合征(ACS)患者90例,随机分为两组,对照组45例,予西药β受体阻滞剂、抗凝素、降脂剂常规治疗,4周为1疗程;实验组45例,在...目的丹红注射液对急性冠脉综合征(ACS)患者血浆脑钠肽(BNP)及心率变异性(HRV)的影响。方法选取我院收治的急性冠脉综合征(ACS)患者90例,随机分为两组,对照组45例,予西药β受体阻滞剂、抗凝素、降脂剂常规治疗,4周为1疗程;实验组45例,在常规治疗的基础上加用丹红注射液,20 m L,加入5%葡萄糖注射液100 m L内滴注,1次/d,4周为1疗程。比较2组患者治疗后血浆脑钠肽(BNP)水平、心率变异性(HRV)指标SDNN、SDANN、RMSSD、PNN50%变化及中医症状(包括胸闷、短气、心痛)改善情况。结果 1)血浆脑钠肽(BNP)水平比较,治疗后实验组(93.8)较对照组(145.2)显著下降,差异有统计学意义(P<0.05)。2)心率变异性(HRV)各指标,治疗后实验组(SDNN:103.2±13.1、SDANN:98.1±18.9、RMSSD:29.9±16.2、PNN50%:5.9±3.2)较对照组(SDNN:99.2±13.7、SDANN:87.2±19.8、RMSSD:26.1±10.3、PNN50%:4.3±3.9)显著升高,差异有统计学意义(P<0.05)。3)胸闷、短气、心痛等中医症状,治疗后实验组较对照组有显著改善,差异有统计学意义(P<0.05)。结论丹红注射液可有效下调急性冠脉综合征患者的血浆脑钠肽水平、提高SDNN、SDANN、RMSSD、PNN50%等心率变异性参数、改善胸闷、短气、心痛等中医症状。展开更多
基金funded by the Innovation Fund of China Academy of Chinese Medical Sciences(CI2021A04707)China National Science and Technology Major Project for“SignificantNew Drugs Development”(No.2011ZX09304-07)China National Institute of Healthcare Security,Capital Medical University(No.YB2022B10).
文摘Objective:Danhong injection(DHI)is commonly used in China to treat chronic stable angina(CSA),demonstrating significant clinical efficacy and safety.The present study aimed to estimate the cost-effectiveness of DHI combined with standard treatment(ST)compared with ST alone in patients with CSA.Methods:A Markov model with a 3-month cycle and a 1-year time horizon was used to assess the cost-effectiveness of DHI+ST for CSA.Health outcomes were measured as quality-adjusted life years(QALYs),and societal perspective costs were collected in China.Cost-effectiveness was evaluated using the incremental cost-effectiveness ratio(ICER).Sensitivity analysis was performed to test the robustness of results to parameter uncertainty.Results:Analysis demonstrated DHI+ST provided 0.8190 QALYs at an average cost of$3644.24,while ST yielded 0.7884 QALYs costing$2739.54 over 1 year.The incremental analysis indicated DHI+ST dominance,with an ICER of$29,588.91 per QALY gained compared with ST.One-way sensitivity analysis confirmed the robustness of base case findings,and probabilistic sensitivity analysis suggested a 61.66%probability of DHI+ST being cost-effective over ST at a$37,663.26 per QALY threshold.Conclusion:From a societal perspective in China,DHI+ST appears cost-effective for the treatment of CSA compared with ST alone.These findings support recommending DHI as a clinically valuable and cost-effective option in CSA treatment guidelines.
文摘目的丹红注射液对急性冠脉综合征(ACS)患者血浆脑钠肽(BNP)及心率变异性(HRV)的影响。方法选取我院收治的急性冠脉综合征(ACS)患者90例,随机分为两组,对照组45例,予西药β受体阻滞剂、抗凝素、降脂剂常规治疗,4周为1疗程;实验组45例,在常规治疗的基础上加用丹红注射液,20 m L,加入5%葡萄糖注射液100 m L内滴注,1次/d,4周为1疗程。比较2组患者治疗后血浆脑钠肽(BNP)水平、心率变异性(HRV)指标SDNN、SDANN、RMSSD、PNN50%变化及中医症状(包括胸闷、短气、心痛)改善情况。结果 1)血浆脑钠肽(BNP)水平比较,治疗后实验组(93.8)较对照组(145.2)显著下降,差异有统计学意义(P<0.05)。2)心率变异性(HRV)各指标,治疗后实验组(SDNN:103.2±13.1、SDANN:98.1±18.9、RMSSD:29.9±16.2、PNN50%:5.9±3.2)较对照组(SDNN:99.2±13.7、SDANN:87.2±19.8、RMSSD:26.1±10.3、PNN50%:4.3±3.9)显著升高,差异有统计学意义(P<0.05)。3)胸闷、短气、心痛等中医症状,治疗后实验组较对照组有显著改善,差异有统计学意义(P<0.05)。结论丹红注射液可有效下调急性冠脉综合征患者的血浆脑钠肽水平、提高SDNN、SDANN、RMSSD、PNN50%等心率变异性参数、改善胸闷、短气、心痛等中医症状。
